These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 16684078

  • 1. The CARI guidelines. Management of bone disease, calcium, phosphate and parathyroid hormone.
    Elder G, Faull R, Branley P, Hawley C, Caring for Australasians with Renal Impairment (CARI).
    Nephrology (Carlton); 2006 Apr; 11 Suppl 1():S230-61. PubMed ID: 16684078
    [No Abstract] [Full Text] [Related]

  • 2. [Chronic kidney disease (CKD) and bone. Management of chronic kidney disease-mineral and bone disorder in peritoneal dialysis patients].
    Yaginuma T, Yamamoto H.
    Clin Calcium; 2009 Apr; 19(4):508-13. PubMed ID: 19329829
    [Abstract] [Full Text] [Related]

  • 3. [Chronic kidney disease (CKD) and bone. Targets of serum calcium, phosphate, and parathyroid hormone levels and their controls in maintenance dialysis patients].
    Akiba T.
    Clin Calcium; 2009 Apr; 19(4):537-44. PubMed ID: 19329833
    [Abstract] [Full Text] [Related]

  • 4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 5. How many measurements to make a decision?
    Houillier P, Coste J, Froissart M.
    Clin J Am Soc Nephrol; 2010 Jul; 5(7):1161-2. PubMed ID: 20558565
    [No Abstract] [Full Text] [Related]

  • 6. The CARI guidelines. Biochemical targets.
    Hawley C, Elder G, Caring for Australasians with Renal Impairment (CARI).
    Nephrology (Carlton); 2006 Apr; 11 Suppl 1():S198-216. PubMed ID: 16684076
    [No Abstract] [Full Text] [Related]

  • 7. Effects of dialysis prescription on bone and mineral metabolism: the National Cooperative Dialysis Study.
    Harter HR, Laird NM, Teehan BP.
    Kidney Int Suppl; 1983 Apr; (13):S73-9. PubMed ID: 6345900
    [No Abstract] [Full Text] [Related]

  • 8. [Systemic diseases affecting the skeletal system].
    Hehrmann R, Eliwo-Bamokyaka M.
    Z Gastroenterol Verh; 1986 Apr; 21():27-34. PubMed ID: 2422837
    [No Abstract] [Full Text] [Related]

  • 9. Treatment of hyperparathyroidism--why is it crucial to control serum phosphate?
    Brancaccio D, Gallieni M, Cozzolino M.
    Nephrol Dial Transplant; 1996 Mar; 11(3):420-3. PubMed ID: 8671808
    [No Abstract] [Full Text] [Related]

  • 10. Which of the K/DOQI guidelines for bone disease in dialysis patients should be changed?
    Gal-Moscovici A, Sprague SM, Hutchison AJ, Shah N, Piraino B, Cunningham J.
    Semin Dial; 2007 Mar; 20(1):24-32. PubMed ID: 17244115
    [No Abstract] [Full Text] [Related]

  • 11. Osteopenia during long-term haemodialysis: response to vitamin D3 analogues.
    Muirhead N, Adami S, Fraser RA, Catto GR, Edward N, O'Riordan JL.
    Proc Eur Dial Transplant Assoc; 1981 Mar; 18():567-72. PubMed ID: 6895786
    [No Abstract] [Full Text] [Related]

  • 12. Vitamin D deficiency and associated factors in hemodialysis patients.
    Jean G, Charra B, Chazot C.
    J Ren Nutr; 2008 Sep; 18(5):395-9. PubMed ID: 18721733
    [Abstract] [Full Text] [Related]

  • 13. National haemodialysis guidelines: an assessment of compliance from 2001-2003.
    Bannister KM, Snelling P, Australian Renal Anaemia Group.
    Nephrology (Carlton); 2006 Apr; 11(2):90-6. PubMed ID: 16669967
    [Abstract] [Full Text] [Related]

  • 14. [Vitamin D and bone disease due to dialysis].
    Kurokawa K.
    Nihon Naika Gakkai Zasshi; 1992 Sep 10; 81(9):1397-400. PubMed ID: 1333507
    [No Abstract] [Full Text] [Related]

  • 15. Calcium and the endocrine system.
    O'Riordan LH.
    Practitioner; 1982 Feb 10; 226(1364):237-41. PubMed ID: 6896382
    [No Abstract] [Full Text] [Related]

  • 16. Renal osteodystrophy and its treatment.
    Duursma SA, Mees EJ.
    Neth J Med; 1973 Feb 10; 16(2):101-7. PubMed ID: 4705764
    [No Abstract] [Full Text] [Related]

  • 17. Residual renal function plays an important role in regulating parathyroid hormone in patients on continuous ambulatory peritoneal dialysis.
    Okada S, Inoue T, Nakamoto H, Ikeda N, Sugahara S, Shoda J, Okada H, Kanno Y, Suzuki H.
    Adv Perit Dial; 2007 Feb 10; 23():150-4. PubMed ID: 17886623
    [Abstract] [Full Text] [Related]

  • 18. Low-calcium dialysate worsens secondary hyperparathyroidism.
    Argilés A, Mion CM.
    J Am Soc Nephrol; 1996 Apr 10; 7(4):635-6. PubMed ID: 8724901
    [No Abstract] [Full Text] [Related]

  • 19. Mineral metabolism parameters throughout chronic kidney disease stages 1-5--achievement of K/DOQI target ranges.
    Craver L, Marco MP, Martínez I, Rue M, Borràs M, Martín ML, Sarró F, Valdivielso JM, Fernández E.
    Nephrol Dial Transplant; 2007 Apr 10; 22(4):1171-6. PubMed ID: 17205962
    [Abstract] [Full Text] [Related]

  • 20. Limitation by hyperphosphataemia of the "prophylactic" use of vitamin D metabolites in the treatment of osteitis fibrosa in patients on chronic haemodialysis.
    de Fremont JF, Sebert JL, Gueris J, Marie P, Coevoet B, Makdassi R, Lambrey G, Meunier P, Fournier A.
    Proc Eur Dial Transplant Assoc; 1979 Apr 10; 16():675-6. PubMed ID: 232918
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.